CIBC Private Wealth Group
KROS icon

CIBC Private Wealth Group’s Keros Therapeutics KROS Stock Holding History

CIBC Private Wealth Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-250
Closed -$14.5K – 3085
2024
Q3 		$14.5K Buy
+250
New +$12.3K ﹤0.01% 2288

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

CIBC Private Wealth Group's KROS Position: Q4 2024 in Review

CIBC Private Wealth Group sold out of Keros Therapeutics (KROS) in Q4 2024, closing a stake of 250 shares — an estimated $14.5K sold.

CIBC Private Wealth Group first reported a position in KROS in Q3 2024 and held it in 1 quarter. The position peaked at $14.5K in Q3 2024. 161 funds tracked by Wall St. Rank hold KROS as of Q4 2024.

  • CIBC Private Wealth Group reported no remaining Keros Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CIBC Private Wealth Group sold 250 Keros Therapeutics shares in Q4 2024, an estimated $14.5K.
  • CIBC Private Wealth Group first reported a position in Keros Therapeutics in Q3 2024 and held it in 1 quarter.
  • CIBC Private Wealth Group's Keros Therapeutics position peaked at $14.5K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2024.

Based on CIBC Private Wealth Group's 13F filing for Q4 2024, filed 12 Feb 2025.